Cardiomyocytes execute pro- and anti-inflammatory signaling of IFNγ-induced GBP5 by differential regulation of the inflammasome

This study reveals that cardiomyocytes possess an intrinsic immunocompetent capacity where IFNγ-induced GBP5 drives a pro-inflammatory AIM2/CASP1 pathway while simultaneously engaging a non-canonical GBP5/TGFβ axis to exert anti-inflammatory feedback, thereby resolving the cytokine's paradoxical roles in cardiac inflammation.

The Gist

The Big Picture: The Heart's "Self-Defense" System

Imagine your heart is a bustling city. Usually, when the city gets attacked (by a virus, a heart attack, or stress), the police and fire department (immune cells) rush in to handle the damage. For a long time, scientists thought the heart muscle cells themselves were just the "buildings" being damaged—passive victims waiting for help.

This paper reveals a surprising twist: The heart muscle cells are actually armed and capable of fighting back on their own. They aren't just buildings; they are like "smart buildings" with their own internal security systems.

The study focuses on a specific signal called IFNγ (Interferon-gamma). Think of IFNγ as a siren or a distress flare sent out during an infection or injury. In the past, scientists thought this siren only meant "Call the police! Everything is on fire!" (pure inflammation). However, this paper shows that the siren actually triggers a complex, two-sided response in the heart cells: it starts a fire and brings in the water hose at the same time.

The Key Player: GBP5 (The "Swiss Army Knife" of the Cell)

The star of this show is a protein called GBP5.

• The Old View: In immune cells (like white blood cells), GBP5 is like a matchstick. When the siren (IFNγ) goes off, GBP5 lights a fire to destroy invaders.
• The New Discovery: In heart muscle cells, GBP5 acts more like a thermostat or a dimmer switch.

When the heart cell hears the IFNγ siren, it quickly turns up the heat (inflammation) to fight the threat. But almost immediately, it uses GBP5 to turn the heat down again so the heart doesn't burn itself out.

The Story Unfolds: Step-by-Step

1. The Alarm Rings (IFNγ Stimulation)

When the heart is stressed, IFNγ arrives.

• In the Rat Heart (The Lab Model): The heart cells immediately wake up. They activate a specific alarm system called the AIM2 inflammasome (think of this as a specialized smoke detector that triggers a sprinkler system).
• The Twist: They don't activate the other common alarm system (NLRP3). It's like they have a specific key for this specific lock.

2. The "Fire" and the "Water" (Pro- vs. Anti-Inflammatory)

The study found that the heart cells do two things at once:

1. They start the fire: They produce inflammatory signals to fight the threat.
2. They bring the water: They produce a protein called TGFβ (a "calming agent") to stop the fire from getting out of control.

The Analogy: Imagine a house with a smart security system. When a burglar is detected, the system screams (inflammation) to scare the thief, but it also automatically locks the doors and turns on the sprinklers (anti-inflammatory) to prevent the house from burning down while the police arrive.

3. The GBP5 "Brake"

The researchers played a game of "what if" with the GBP5 protein:

• If you remove GBP5: The heart cells lose their "brake." The inflammation goes wild, the "calming agent" (TGFβ) disappears, and the heart cells start dying. It's like taking the brakes off a car going downhill; it speeds out of control and crashes.
• If you add extra GBP5: The heart cells become super-resistant. Even when the siren (IFNγ) is screaming, the GBP5 keeps the inflammation in check, protecting the cell from damage.

4. Species Differences (Rats vs. Humans)

The researchers tested both rat heart cells and human heart cells (grown from stem cells).

• Rats: Reacted very fast.
• Humans: Reacted a bit slower and differently, but the core lesson remained the same: Human heart cells also have this self-regulating "GBP5 brake."

This is crucial because it means we can't just assume what happens in a rat heart happens exactly the same way in a human heart. We need to be careful when designing drugs.

Why Does This Matter?

Heart failure, myocarditis (heart inflammation), and damage from cancer drugs often involve too much inflammation. The heart gets so "angry" and inflamed that it stops pumping effectively.

This paper suggests a new way to think about treatment:

• Instead of just trying to "turn off" the immune system (which might leave you vulnerable to infection), maybe we should boost the heart's own "GBP5 brake."
• By helping the heart cells regulate their own inflammation, we might be able to stop the heart from damaging itself during a crisis.

The Takeaway in One Sentence

The heart muscle isn't a helpless victim; it has a sophisticated internal "dimmer switch" (GBP5) that lets it fight infections while simultaneously protecting itself from burning out, a mechanism that could be the key to treating heart failure.

Technical Summary

1. Problem Statement

Interferon-gamma (IFNγ) is a pleiotropic cytokine known to drive innate immune signaling in damaged myocardium. While traditionally viewed as a pro-inflammatory cytokine, IFNγ exhibits paradoxical context-dependent roles, acting as both an inducer and a negative regulator of inflammation in various cardiomyopathies (ischemic, non-ischemic, and drug-induced).

• Knowledge Gap: Current understanding of IFNγ signaling in the heart relies heavily on immune cells (macrophages, T cells). The intrinsic immunoregulatory potential of cardiomyocytes themselves remains poorly understood.
• Specific Question: How do cardiomyocytes autonomously regulate the inflammasome pathway in response to IFNγ, and what molecular mechanisms allow them to balance pro- and anti-inflammatory signals to prevent tissue damage?

2. Methodology

The study employed a comparative approach using two distinct cardiomyocyte models:

• Cell Models:
  • Neonatal Rat Ventricular Cardiomyocytes (NRVCMs): Isolated from 1–3 day old Wistar rats.
  • Human Induced Pluripotent Stem Cell-derived Cardiomyocytes (hiPSC-CMs): Generated via small-molecule differentiation and glucose starvation enrichment.
• Stimulation Protocols:
  • Type II IFN: Stimulation with IFNγ (10 ng/mL).
  • Type I IFN: Stimulation with Poly:IC or Lipopolysaccharide (LPS).
• Genetic Manipulation:
  • Knockdown: siRNA-mediated silencing of GBP5 in both NRVCMs and hiPSC-CMs.
  • Overexpression: Adenoviral transduction (5 MOI) of human GBP5 into NRVCMs and hiPSC-CMs.
• In Vivo Models:
  • Mice subjected to Left Anterior Descending (LAD) artery ligation (ischemic model) or O-ring Aortic Banding (ORAB) for hypertrophy (non-ischemic model) to assess endogenous GBP5 expression.
• Analytical Techniques:
  • Molecular: qRT-PCR for gene expression (inflammasome components, cytokines); Western Blotting for protein levels (STAT1, GBP5, CASP1, OXPHOS complexes).
  • Imaging: Immunofluorescence for protein localization (STAT1 nuclear vs. GBP5 cytoplasmic/Golgi).
  • Functional Assays:
    • Contractility: Microscopy-based assay measuring contraction amplitude and velocity.
    • Metabolism: Seahorse XF Cell Mito Stress Test for Oxygen Consumption Rate (OCR).
    • Viability/Apoptosis: MTT assay and TUNEL assay.

3. Key Contributions

• Cell-Autonomous Immunocompetence: Demonstrated that cardiomyocytes are not merely passive targets of inflammation but possess an intrinsic, cell-autonomous ability to regulate inflammasome signaling upon IFN stimulation.
• Species-Specific Differential Regulation: Revealed distinct differences between rodent and human cardiomyocytes regarding the timing and magnitude of inflammasome component expression (e.g., delayed GBP5 response in human cells).
• The GBP5/TGFβ Axis: Identified a novel non-canonical feedback loop where IFNγ-induced GBP5 upregulates TGFβ to exert an anti-inflammatory brake, preventing runaway inflammation.
• Inflammasome Specificity: Clarified that IFNγ selectively activates the AIM2/CASP1 pathway in cardiomyocytes while leaving NLRP3 levels unaltered, contrasting with Type I IFN stimulation which upregulates NLRP3.

4. Key Results

A. Differential Inflammasome Regulation by IFN Type

• Type II IFN (IFNγ): In both NRVCMs and hiPSC-CMs, IFNγ robustly upregulated GBP5, AIM2, CASP1, and IL1β. Crucially, NLRP3 levels remained unchanged.
• Type I IFN (Poly:IC/LPS): Induced canonical inflammasome signaling with upregulation of NLRP3, CASP1, and IL1β.
• Kinetics: In hiPSC-CMs, CASP1 increased early, followed by a delayed peak in GBP5 mRNA (24h) and protein. GBP5 protein localized to the cytoplasm (Golgi-associated), while STAT1 translocated to the nucleus.

B. The Paradoxical Role of GBP5

Contrary to its known pro-inflammatory role in immune cells, GBP5 acts as an anti-inflammatory regulator in cardiomyocytes:

• GBP5 Knockdown:
  • Led to a pro-inflammatory phenotype: Increased STAT1, CCL2, NLRP3, IL18, and IL1β.
  • Decreased anti-inflammatory markers (TGFβ, IL10).
  • Resulted in increased cell death (TUNEL positive) and impaired contractility when stimulated with IFNγ.
• GBP5 Overexpression:
  • Attenuated IFNγ-induced expression of inflammatory markers (CCL2, STAT1, AIM2, CASP1).
  • Prevented the escalation of TGFβ (suggesting a feedback saturation mechanism).
  • Did not further increase cell death, indicating a protective role.

C. Functional Consequences

• Contractility: IFNγ stimulation impaired cardiomyocyte contractility (reduced amplitude and velocity).
• Mitochondrial Function: IFNγ reduced basal Oxygen Consumption Rate (OCR) and decreased levels of OXPHOS complexes (I–IV).
• Cell Death: GBP5 deficiency exacerbated IFNγ-induced apoptosis, whereas overexpression did not worsen it, confirming GBP5's protective capacity against inflammatory cell death.

D. In Vivo Relevance

• Mice with ischemic (LAD) or hypertrophic (ORAB) heart failure showed significantly elevated GBP5 expression in the left ventricle, linking the in vitro findings to pathological cardiac states.

5. Significance

• Mechanistic Insight: This study resolves the paradox of IFNγ's dual role in the heart by identifying GBP5 as a critical rheostat. It suggests that cardiomyocytes utilize a GBP5/AIM2/CASP1/TGFβ cascade to generate a controlled, adaptive inflammatory response rather than a destructive one.
• Therapeutic Implications:
  • Current therapies targeting inflammasomes (e.g., IL-1β inhibitors like Canakinumab) may need re-evaluation in the context of cardiomyocyte-specific GBP5 regulation.
  • Enhancing GBP5 expression or the GBP5/TGFβ axis could represent a novel strategy to mitigate sterile inflammation in heart failure and myocarditis without suppressing necessary immune responses.
• Translational Caution: The study highlights significant species-specific differences (rat vs. human) in inflammasome kinetics and regulation, urging caution when extrapolating rodent data directly to human cardiac pathophysiology.

In conclusion, the paper establishes cardiomyocytes as active immunoregulatory agents that utilize GBP5 to balance pro-inflammatory signaling with anti-inflammatory feedback, preventing excessive tissue damage during IFNγ-driven cardiac stress.